Schonfeld Strategic Advisors’s Cidara Therapeutics CDTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,800	Closed	-$839K	–	2272
2025 Q4	$839K	Buy	+3,800	New	+$614K	﹤0.01%	1192

Schonfeld Strategic Advisors's CDTX Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 19,537 shares — an estimated $4.32M sold.

Schonfeld Strategic Advisors first reported a position in CDTX in Q1 2022 and held it in 12 quarters. The position peaked at $4.32M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Schonfeld Strategic Advisors reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Schonfeld Strategic Advisors sold 19,537 Cidara Therapeutics shares in Q1 2026, an estimated $4.32M.
Schonfeld Strategic Advisors first reported a position in Cidara Therapeutics in Q1 2022 and held it in 12 quarters.
Schonfeld Strategic Advisors's Cidara Therapeutics position peaked at $4.32M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.